The size of the France OTC Drugs market is estimated to be USD 4.12 billion in 2022 and is projected to reach USD 4.89 billion by 2027, growing at a CAGR of 3.5% in the review period.
Pharmacies are highly prevalent throughout the country and over the counter (OTC) drugs are considered safe and are widely used by a significant population in France. People are encouraged by the government to try non-prescriptive drugs before visiting a doctor to ease the pressure on the health service. Paracetamol, aspirin, and ibuprofen are the most widely used OTC drugs in France.
Ease of access, convenience, and low cost are driving the OTC market in France. When most of the countries are considering restricting OTC sales of certain drugs, French authorities are moving in the opposite direction. Liberalizing the sales of OTC drugs is also likely to dampen the public’s expenditure on health and increase its sales. Increasing access to new channels, the cultural shift of the public towards self-medication is also fuelling the growth of the market. Online pharmacies are also being launched in France making the over the counter drugs more accessible.
However, the non-availability of reimbursements through government insurance schemes is a major setback for the OTC drug markets. The prices have also gone up in the last decade as a result of pharmacist’s monopoly on the retail segment. These along with the issues pertaining to drug substance abuse are restraining the growth of the market.
This research report is segmented & sub-segmented the France OTC Drugs Market into the following categories:
Key market participants leading France Over the Counter Drugs Market profiled in this report are Eu Yan Sang International Ltd, Bayer AG, Johnson & Johnson, GlaxoSmithKline plc, Merck Pte Ltd, Sunward Pharmaceutical Pte Ltd, Beacons Pharmaceuticals (Pte) Ltd.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1200
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com